TP53 and serous adenocarcinoma: Today, many of the formerly diagnosed “high-grade endometrioid” carcinomas are classified as high-grade serous carcinoma, which is supported by molecular evidence (e.g., combination of WT1 expression with TP53 mutation or BRCA1/2 mutations) [7,8,9,10].